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DII; dietary inflammatory index 
CHD; coronary heart disease  
MedDiet; Mediterranean diet 
CRP; C-reactive protein 
TNF-α; Tumor necrosis factor-α 
IL; interleukin  
CONSORT; Consolidated Standards of Reporting Trials 
AMI; acute myocardial infarction 
MUFA; monounsaturated fatty acids 
PUFA; polyunsaturated fatty acids 
EVOO; extra virgin olive oil  
MVPA; moderate-to-vigorous physical activity 
MEDAS; Mediterranean Diet Adherence Screener 
Hs; high sensitivity  
ELISA; enzyme‐linked immunosorbent assay 
SD; standard deviation 
IQR; interquartile range  
ANCVOA; Analysis of covariance 
CI; confidence interval 






























A higher dietary inflammatory index (DII
®
) score is associated with inflammation and 
incidence of coronary heart disease (CHD). We hypothesized that a Mediterranean diet 
(MedDiet) intervention would reduce DII score. We assessed dietary data from a randomized 
controlled trial comparing 6-month MedDiet versus low-fat diet intervention, in patients with 
CHD. We aimed to determine the DII scores of the prescribed diets’ model meal plans, 
followed by whether dietary intervention led to lower (i.e., more anti-inflammatory) DII 
scores and consequently lower high sensitivity C-reactive protein (hs-CRP) and interleukin-6 
(hs-IL-6). DII scores were calculated from 7-day food diaries. The MedDiet meal plan had a 
markedly lower DII score than the low-fat diet meal plan (-4.55 vs. -0.33, respectively). In 56 
participants who completed the trial (84% male, mean age 62±9 years), the MedDiet group 
significantly reduced DII scores at 6-months (n=27; -0.40±3.14 to -1.74±2.81, p=0.008) and 
the low-fat diet group did not change (n=29; -0.17±2.27 to 0.05±1.89, p=0.65). There was a 
significant post-intervention adjusted difference in DII score between groups (compared to 
low-fat, MedDiet decreased by -1.69 DII points; p=0.004). When compared to the low-fat 
diet, the MedDiet non-significantly reduced hs-IL-6 (-0.32pg/mL, p=0.29) and increased hs-
CRP (+0.09mg/L, p=0.84). These findings demonstrated that MedDiet intervention 
significantly reduced DII scores compared to a low-fat diet. However, in this small cohort of 
patients with CHD this did not translate to a significant improvement in measured 
inflammatory markers. The effect of improvement in DII with MedDiet should be tested in 
larger intervention trials and observational cohorts.  
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Chronic, low-grade systemic inflammation is a recognized risk factor for development of 
chronic diseases, including coronary heart disease (CHD)[1]. Dietary intakes have been 
shown to affect inflammation via both pro-inflammatory and anti-inflammatory 
mechanisms[2]. Healthy dietary patterns, which focus on foods rather than single nutrients, 
have been shown to be anti-inflammatory[3, 4]. Among these, the Mediterranean diet 
(MedDiet) has the strongest evidence for improvement in markers of inflammation[5, 6]. 
However, the effect of the MedDiet on biomarkers of inflammation is unclear in patients with 
CHD[7].  
 
The Dietary Inflammatory Index (DII
®
) is a literature-derived dietary score which 
incorporates 45 nutritional factors that are known to modulate inflammatory markers, in 
either a pro- or anti-inflammatory manner[8]. This method of characterizing diet differs from 
other dietary pattern adherence scores as it was formulated based on findings evident in the 
literature relating diet to inflammatory cytokine signaling pathways. This is fundamentally 
different than patterns of food intake that are associated with a particular set of dietary 
recommendations (e.g., the Alternative Healthy Eating Index in relation to the American 
Food Pyramid)[9] or a culinary tradition (e.g., the MedDiet)[10]. Since its development, the 
DII has been applied to diet intake data in a variety of study cohorts to indicate associations 
with cardiovascular risk factors and CHD[11]. A higher (more pro-inflammatory) DII score 
has been associated with the inflammatory markers C-reactive protein (CRP)[12], tumor 
necrosis factor-alpha (TNF-α)[13], and interleukin (IL)-6[14], incidence of metabolic 














cardiovascular events[17-19]. The DII offers an attractive alternative assessment tool to 
laboratory-based measurement of inflammatory cytokines, which are obtained through 
invasive means, tend to be costly, and are not routinely available in existing studies. 
 
The DII also provides a method by which established dietary patterns can be compared for 
their probable anti-inflammatory effect. For instance, a one-day meal plan of a traditional 
MedDiet had a strong anti-inflammatory DII score[20] and greater MedDiet adherence has 
been negatively associated with DII scores[16, 21]. The DII also has been demonstrated to be 
inversely associated with healthy eating scores based on American dietary guidelines[9].  
 
An improvement in DII score can therefore be achieved through healthy diet intervention, 
which in turn could reduce inflammation and other cardiometabolic risk markers, as well as 
prevent CHD. To our knowledge only two studies have assessed the impact of diet 
intervention on the DII. One of these trials showed short (2-month), but not longer-term (6-
month), improvement in DII with vegetarian compared to omnivorous diets in a small cohort 
(n=63) of overweight adults[22]. The other study of a large cohort (n=14, 339) of post-
menopausal women reported modest improvement in DII after 6-years on a low-fat diet[23]. 
Neither of these studies, however, assessed whether the reduction in DII score achieved with 
improved diet led to a change in inflammatory markers.  
 
Current recommendations in Australia promote a low-fat diet for the prevention of CHD[24], 
for which there is some evidence to suggest this type of diet is associated with reduced DII 
scores[9]. A MedDiet, by nature of its composition, is likely to lead to a more anti-
inflammatory DII score. The impact of adherence to a MedDiet on DII scores is of interest 














grade, systemic inflammation. Therefore, our objectives were to determine (1) how the DII 
score of a MedDiet compared with that of a low-fat diet, (2) the impact of randomization to 
an intervention with these two diets for 6-months on change in DII score and CRP and IL-6 
(two inflammatory biomarkers on which the DII development was based)[8], and (3) the 
association between improvement in MedDiet adherence score and DII score, in an adult 
population with CHD. We hypothesized that the prescribed MedDiet model would have a 
lower DII score (i.e., greater dietary anti-inflammatory potential) than that of the low-fat diet, 
and that this would translate to greater improvement in DII score and inflammation in 
participants randomized to the MedDiet intervention. We also hypothesized an association 
between improvement in MedDiet adherence and DII scores.   
 
2. Methods and Materials 
 
2.1. Study design  
 
The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial) is a multicenter, 
parallel design, randomized controlled trial (RCT) for the secondary prevention of CHD in a 
multi-ethnic Australian population (Australia and New Zealand Clinical Trials Register: 
ACTRN12616000156482, http://www.anzctr.org.au/). The trial involves 6-month 
intervention with a MedDiet versus low-fat diet and a 12-month follow up to assess the 
primary outcome of aggregate cardiovascular events. The present study investigated the 6-
month effect of two dietary interventions (MedDiet and low-fat diet) and the impact that 
MedDiet adherence had on DII scores (i.e., inflammatory potential of the diet), as well as the 















2.2. Participants and recruitment  
 
Between 2014 to 2016, patients were recruited from two teaching hospitals in Melbourne, 
Australia. The study is being conducted in accordance with the CONSORT guidelines[25] 
and the guidelines laid down in the Declaration of Helsinki[26]. All procedures involving 
patients were approved by the Human Research Ethics Committees of La Trobe University, 
the Northern Hospital and St Vincent’s Hospital Melbourne, with written informed consent 
obtained from all enrolled participants. 
 
Eligible patients were adults with CHD, able to read and write in English, and who had 
experienced at least one of the following: acute myocardial infarction (AMI); angina pectoris 
with documented coronary artery disease on imaging; coronary artery bypass grafting; or 
percutaneous coronary intervention. Exclusion criteria included: malignant tumor, 
symptomatic chronic heart failure (New York Heart Association Functional Classification II, 
III & IV[27]), chronic inflammatory disease requiring immunosuppressant or non-steroidal 
anti-inflammatory drugs, chronic kidney disease stage 3 or above[28], decompensated liver 
disease (or taking medications that cause hepatosteatosis), pregnancy or breastfeeding, 
history of allergy to olive oil or nuts, or current participation in a lifestyle program, drug or 
supplement trial. Patients were approached at outpatient, rehabilitation or inpatient cardiac 
settings. Eligible and interested patients attended a pre-baseline appointment where the study 
was explained in detail, forms and equipment were provided, consent was obtained and 
randomization was conducted. 
 















Enrolled participants were randomly assigned in a 1:1 ratio to the MedDiet group or the low-
fat diet group. Randomization tables were developed by the trial statistician using a computer 
generated stratified approach based on sex, age (<55, 55 to 65 and >65 years) and history of 
AMI (yes/no). Baseline, 3-month and 6-month face-to-face appointments were conducted to 
obtain anthropometry, biomarkers and dietary data and for counselling with the dietitian. Five 
short phone reviews for follow-up dietary counselling with the dietitian also occurred across 
the 6-months, at weeks 3, 6, and 9 and months 4 and 5. Telephone-delivered lifestyle advice 
previously has been demonstrated to be effective for reducing coronary risk factors in the 
Australian setting and is a low-cost intervention method[29]. Different dietitians worked with 
the two different diet study groups to prevent contamination. Consultation frequency and data 
collection time points were consistent across the two intervention groups. All participants 
continued to receive standard medical care provided at their respective hospital or primary 
care settings; however, they were instructed not to engage in any nutritional interventions, 
including cardiac rehabilitation or other research trials for the duration of this study.  
 
2.3.1. Mediterranean diet  
 
The rationale and development of the MedDiet intervention has been explained in detail 
elsewhere (George, et al., 2018, manuscript under preparation). It was designed based on the 
principles of the traditional Cretan MedDiet[30], including information from seminal 
intervention trials conducted in Mediterranean populations[31, 32], trials conducted in 
Australia where MedDiet foods and meals were provided[33, 34] and the Hellenic dietary 
guidelines[35]. The diet was modelled via a 2-week meal plan incorporating key dietary 
components of a MedDiet and a mix of traditional and modified recipes considered to be 














consumption, target macronutrient intakes were 42% total fat (of which at least 50% was 
from monounsaturated fatty acids [MUFA] and 25% from polyunsaturated fatty acids 
[PUFA]), <10% saturated fatty acids, 35% carbohydrate, 15% protein, and ≤5% alcohol.   
 
Participants were provided with the 2-week model meal plan (Table S1 in Supplemental 
Materials provides an example of one day), the MedDiet resource kit which is to be published 
in George, et al., 2018 (manuscript under preparation), an associated recipe book, The 
Mediterranean Diet by Itsiopoulos (2013) (ISBN 9781742610825), and shopping list. Other 
resources provided included a food pyramid, weekly food intake checklist and label reading 
information. Food group recommendations included: daily intake of extra virgin olive oil 
(EVOO), nuts, vegetables, fruit and wholegrain cereals, regular intake of legumes, fish and 
yoghurt, and limited intake of commercial sweets or pastries and red or processed meat. 
Poultry, eggs and feta cheese were recommended in moderation. For participants choosing to 
consume alcohol, red wine was suggested to be consumed in moderation (1-2 standard 
glasses) with meals. To facilitate dietary compliance and to encourage intake of staple 
Mediterranean foods less familiar to this population, a hamper was provided to participants at 
baseline and 3-months. Each hamper included 6L EVOO (to achieve 60-80mL/day) and 
1.2kg nuts (almonds, walnuts and hazelnuts to achieve 30g/day) as well as samples of tinned 
tuna and salmon, canned legumes and Greek yoghurt.  
 
2.3.2. Low-fat diet  
 
Participants in the low-fat diet group were instructed to follow the standard diet 
recommendations provided to cardiac patients in Australia at the time this study was 














group. Recommendations from the Australian National Heart Foundation as well as the 
Australian Dietary Guidelines and Nutrient Reference Values were consulted for design of 
the low-fat diet[24, 36, 37]. In terms of contribution to total energy consumption, target 
macronutrient intakes were <30% total fat, <7% saturated fat, 45-65% carbohydrate, 15-25% 
protein and ≤5% alcohol. Food group recommendations included daily intake of grains and 
cereals (mostly whole grains, 5-7 serves/day), vegetables (5-6 serves/day), fruit (2 
serves/day), protein foods (2-3 serves/day) and low-fat dairy foods (2 serves/day)[36]. Based 
on macronutrient and food group targets, a 1-week meal plan was created to model a 
comparative nutrient profile for this diet and to generate a resource for participants (Table S1 
in Supplemental Materials provides an example of one day). Resources for label reading, 
low-fat cooking and recommended daily food group serves also were provided. To aid 
compliance and encourage their continuation in the trial, participants were provided with a 
supermarket voucher at their three face-to-face appointments. 
 
In both study groups the dietary advice was tailored to each individual through client-
centered counselling and goal setting with the dietitian[38, 39]. Both diets were prescribed ad 
libitum to achieve weight maintenance with no specific recommendations on energy 
restriction. There was some cross-over in the general food group recommendations between 
the low-fat diet and the MedDiet, including daily intake of vegetables, fruit and wholegrain 
cereals and limited processed foods. However, the MedDiet specifically included promotion 
of EVOO, nuts, leafy greens, tomatoes, onion, garlic, legumes, oily fish and fermented dairy 
foods and more significantly reduced intake of red meat, which were not key components of 
the low-fat diet[40]. 
 















This study reports only on baseline and 6-month data measurements. Medical conditions 
related to eligibility were collected in the screening process using hospital records and by 
questionnaire at the pre-baseline appointment. Sociodemographic and clinical characteristics 
were collected through a self-report survey completed at baseline, which included details on 
type, dose and frequency of medication and supplement use. Exercise was not a target of this 
intervention, however physical activity levels were assessed by triaxial Actigraph 
accelerometer (WGT3X-BT; Actigraph Corp, Florida, United States) worn by participants 7 
days prior to each face-to-face appointment. Time spent in moderate-to-vigorous physical 
activity (MVPA) minutes per week was determined based on established criteria[41]. Weight 
and height were measured, after an 8-h fast, using international standards for anthropometric 
assessment[42] by trained research personnel. Body weight was measured to the nearest 
0.1kg using calibrated digital scales, without shoes and after removal of heavy jewelry, outer 
layers of clothing and pocket contents. Height was measured to the nearest 0.1cm, while 
barefoot using a wall-mounted stadiometer. Body mass index was calculated as weight (kg) / 
height (m
2
) and overweight was classified as >25 kg/m
2
[43]. A fasting blood sample was 
taken from the antecubital vein using standard venous puncture techniques. All blood 
samples were processed immediately and aliquots were stored at -80°C until assay. Serum 
high sensitivity (hs)-CRP levels were measured at a commercial laboratory (Dorevitch 
Pathology Pty Ltd, Heidelberg, Australia) by chemical analyzer (Cobas Integra 400, Roche). 
Serum hs-IL-6 levels were measured by enzyme‐linked immunosorbent assay (ELISA) 
(Abcam, #ab46042, detection sensitivity <0.81 pg/mL) in duplicate. 
 















Participants completed a 7-day food diary in household measures the week prior to the 
baseline and 6-month appointments. The diary included type, brand, quantity and cooking 
methods for consumed foods, with missing details clarified by the dietitian at the 
appointment. All food diaries were entered into FoodWorks8
®
 (Xyris software Australia Pty 
Ltd), using the most up-to-date databases AUSNUT 2013, AusBrands 2015 and AusFoods 
2015 for nutrient intake analyses. Any day recorded in the food diary that was considered to 
represent a highly abnormal intake for the participant was excluded from entry into 
FoodWorks8. This exclusion was applied to only two participants for reasons of religious 
fasting (three days) and nil intake due to acute illness (one day). The 2-week MedDiet and 1-
week low-fat diet meal plans were designed against the desirable macronutrient profile using 
FoodWorks8 analysis. The 14-point Mediterranean Diet Adherence Screener (MEDAS), 
generated and validated for the PREDIMED study[44], was measured at baseline and 6-
months for each participant. Dietitians assisted participants to complete the MEDAS during 
consults for the MedDiet group and calculated the score retrospectively for the low-fat diet 
group using 7-day food diary data in order to avoid contamination with the MedDiet 
principles. A higher score is reflective of better adherence to a traditional MedDiet pattern, 
with a score of 9 or above out of 14 considered an acceptable adherence criterion[45].  
 
2.4.2. Dietary Inflammatory Index (DII®) 
 
The development[8] and validation[12] of the DII has been described elsewhere. Through 
evaluation of peer-reviewed literature published between 1950 and 2010, the DII score is 
based on 1943 articles that examined the association between inflammation and 45 individual 
nutrient, food or flavonoid intake parameters (listed in Table 2). Points were assigned to each 














effect on the four established pro-inflammatory biomarkers; IL-1, IL-6, TNF-α and CRP or 
2) decreased (+1), increased (-1) or had no (0) effect on the two established anti-
inflammatory biomarkers; IL-4 and IL-10. The score for each of the food parameters was 
weighted according to the study design employed and total number of research articles. 
Overall parameter-specific inflammatory effect scores were then calculated based on the ratio 
of the total weighted number of articles to the weighted pro- and anti-inflammatory articles 
for each parameter followed by subtracting the anti- from the pro-inflammatory fraction. 
Parameters which had a robust pool of literature, i.e. greater than the median number of 236 
weighted articles, were assigned the full value of that score. Parameters with the total article 
weight less than 236 were adjusted by dividing it by 236 and then multiplying this fraction by 
the previously defined inflammatory effect score.  
 
In this study, the DII was computed twice in the participants, at baseline and after 6-months 
of intervention. Our assessment of the DII included all 45 of its parameters. Dietary intake 
data were adjusted against a reference global daily mean and standard deviation intake for 
each parameter to obtain a Z-score. The global intake data was based on consumption data 
from 11 countries around the world. To further reduce the effective skewness, each Z score 
was converted to a proportion (i.e., values ranging from 0 to 1) and this value was centered 
on zero by multiplying by 2 and subtracting 1. This centered proportion score for each intake 
parameter was multiplied by its respective parameter-specific inflammatory effect score to 
obtain the parameter-specific DII score. Each of these 45 scores were then summed to obtain 
an overall DII score for each individual and meal plan. Finally, the DII score for participant 















The intake values for most of the DII parameters (energy, protein, carbohydrate, total fat, 
MUFA, PUFA, omega-3, omega-6, saturated fatty acids, trans fat, cholesterol, fiber, alcohol, 
caffeine, folate, beta carotene, vitamin A, vitamin B6, vitamin B12, vitamin C, vitamin E, 
iron, magnesium, niacin, riboflavin, selenium, thiamin and zinc) were obtained from 
FoodWorks8 nutrient analyses of the food diaries or meal plans. For the omega-6 component 
only intake of linoleic acid was available. Isolated food components in the DII (green/black 
tea, garlic, ginger, onion, pepper, rosemary, saffron, turmeric and thyme/oregano) were 
extracted from the food diaries and meal plans and the total daily intake in grams calculated. 
Vitamin D was calculated from the 7-day food diaries and meal plans using an electronic 
Australian nutrient table database[46]. Intake of eugenol was calculated based on the 
recognized content in cloves in Phenol Explorer[47]. For calculation of flavonoids (flavan-3-
ol, flavones, flavonols, flavonones, anthocyanidins and isoflavones) the USDA Databases for 
the Flavonoid Content of Selected Foods (Release 3.2, November 2015) and Isoflavone 
Content of Selected Foods (Release 2.0, September 2008) were used as these databases had a 
wide variety of foods, including data on raw, cooked or processed options.  
 
2.5. Statistical analyses 
 
Participants who did not complete the intervention were excluded from analyses. As this 
study represented an exploratory analysis of a pilot cohort, a power calculation was not 
performed[48]; however, literature was consulted to determine if a significant effect on DII 
could be expected in the current sample. Because randomization to a vegetarian diet 
compared to a healthy omnivorous diet (total n=26) resulted in a significant improvement in 
DII (mean change of −1.4, p<0.05) after 2-months[22], it was therefore expected that our 














associated with even lower DII scores[20] and an even greater reduction in DII than a low-fat 
diet in our participant sample (total n=56) after 6-months.  
 
Data are presented as means ± standard deviation (SD) or standard error (SEM), medians 
(interquartile range [IQR]) or n (%) as appropriate. The Kolmogorov–Smirnov test was 
applied to assess the normality of continuous variables. According to this, an Independent 
Student’s T-test or non-parametric Mann-Whitney U test was used to compare continuous 
variables. Categorical variables were compared using the Chi-square 
 
test. McNemar’s test 
assessed the differences in percentage adherence to each component of the MEDAS between 
baseline and 6-months within each study group. Analysis of covariance (ANCOVA) with 
baseline values as a covariate were performed to assess differences for change in MEDAS, 
DII scores and inflammatory biomarkers between diet study groups, participant tertiles of 
change in MEDAS and adherence to MEDAS components at 6-months. Changes in 
biomarkers also included baseline DII score as a covariate in the ANCOVA models. For all 
analyses based on hs-CRP, participants with serum levels >10mg/L were excluded, as these 
higher concentrations reflect acute rather than chronic inflammation[49]. Pearson or 
Spearman rho correlations were conducted between the MEDAS scores (independent 
variable) and DII scores (dependent variable) at baseline, 6-months and for change variables 
with adjustment for diet intervention group. R-values were classified as weak (0.10 to 0.29), 
moderate (0.30 to 0.49) or strong (0.50 to 1.00) correlations[50]. Statistical significance was 
set at p<0.05, except when multiple post-hoc comparisons were performed within or between 
study groups, in which case a Bonferroni correction was applied. For between- and within-
group comparisons, 95% confidence intervals (CIs) were calculated. All statistical analyses 
were conducted in SPSS
®

















3.1. Participants  
 
Figure 1 demonstrates the randomization to diet study groups and completion of study 
appointments. Of the 35 participants randomized to the low-fat diet group, 31 started and 29 
completed the intervention. Of the 37 participants randomized to the MedDiet group, 35 
started and 27 completed the intervention. Participants dropped out for medical or family 
related issues or were lost to follow up. The drop-outs had a significantly higher pro-
inflammatory DII score, with a mean baseline DII score of 1.76 ± 2.3 compared to -0.28 ± 2.7 
in the completers at baseline (p=0.047). The drop-outs also had a significantly lower median 
intake of fiber at baseline with 19.5 (3.4) vs. 24.9 (15.5) g/day (p=0.01). For all other 
measured variables the drop-outs were similar to those who completed the study.  
 
Sociodemographic, medical and lifestyle characteristics between the diet study groups at 
baseline are reported in Table 1. Overall, the participants represented a middle to older-aged 
adult (mean age 62 ± 9 years), mostly male (84%) group, who were from a variety of ethnic 
backgrounds (55% Australian, 18% Asian, 17% European, 5% British, 4% African and 3% 
North American). More than 80% were overweight, 29% had diagnosed type 2 diabetes 
mellitus and 70% had experienced an AMI. The median time since recent cardiac event was 
less than 6-months. All participants were taking medications, of which the most common 
were anti-platelets (91%), statins (89%) and a range of anti-hypertensives. Less than half the 
cohort were taking nutrient supplements, of which vitamin D (20%), omega-3 (16%) and 
multivitamins (14%) were the most common. Few participants (13%) were current smokers, 














previously seen a dietitian. There were no significant differences between the study groups 
for any of these characteristics at baseline. For intake of energy, contribution to energy from 
macronutrients, and micronutrients there also were no significant differences between the 
study groups. The low-fat diet participants did, however, have a significantly higher median 
intake of fruit compared to the MedDiet group, with 1.9 (1.2) versus 0.9 (1.2) serves per day 
(p=0.006), with no other differences in food group intake at baseline observed.   
 
3.2. DII of model meal plans  
 
Supplementary Table S1 provides an example of one day from each of the intervention diet 
meal plans and Table 2 reports on the mean daily intake for each of the 45 DII parameters 
and DII score for each meal plan. Both meal plans had anti-inflammatory (-) DII scores, but 
the meal plan for the MedDiet was markedly more anti-inflammatory than that of the low-fat 
diet (-4.55 vs. -0.33, respectively). The meal plans comparatively, contained some key 
differences for intake of DII parameters. The MedDiet was higher in the pro-inflammatory 
nutrient parameter of total fat content, but also higher in numerous anti-inflammatory 
parameters of the index (MUFA, PUFA, omega-3 and -6, fiber, alcohol, vitamin A, D and E, 
flavonoids, garlic, onion, rosemary and thyme/oregano).  
 
3.3. Adherence to MedDiet  
 
MEDAS score significantly increased in the MedDiet group from 5.52 ± 2.2 at baseline to 
10.89 ± 1.6 at 6-months (5.37, p<0.001, 95%CI 4.56, 6.18). The low-fat diet group also 
significantly improved their score from 4.76 ± 1.9 at baseline to 6.00 ± 2.0 at 6-months (1.24, 














that in the low-fat diet group, as assessed by ANCOVA, with baseline values as a covariate 
(adjusted difference 5.61, p<0.001, 95%CI 3.11, 8.12). Baseline and 6-month adherence to 
each individual MEDAS component[44] within the two study groups is presented in the 
Supplemental Materials Table S2. Within the MedDiet group, the proportion of participants 
adhering to each of the score components significantly improved (p<0.05), except for olive 
oil quantity (p=0.13), sugar-sweetened beverages (p=0.25) and wine (p=0.38). Within the 
low-fat diet group the only components in the MEDAS score which had significantly 
improved adherence rates were intake of vegetables and reduced use of dairy spreads/cream 
(p<0.05).  
 
3.4. Impact of diet interventions on DII and inflammatory markers 
 
Baseline and 6-month DII scores for the MedDiet and low-fat diet groups are presented in 
Figure 2. Within the MedDiet group there was a significant decrease from -0.40 ± 3.14 to -
1.74 ± 2.8 at 6-months for DII (-1.34, p=0.008, 95%CI -2.33, -0.36), with a similar 
magnitude of change for DIIdiet+supplements (-1.41, p=0.006, 95%CI -3.19, -0.56). Within the 
low-fat diet group the change in DII score from baseline (-0.17 ± 2.27) to 6-months (0.05 ± 
1.89) was not significant (0.22, p=0.65, 95%CI -0.73, 1.17); with a similar result for change 
in DIIdiet+supplements (0.15, p=0.75, 95%CI -0.79, 1.10). The between-group change as 
assessed by ANCOVA, with baseline scores as covariates, demonstrated a significantly 
greater reduction in the MedDiet group compared to low-fat diet group in mean score of DII 
(adjusted difference -1.69, p=0.004, 95%CI -2.82, -0.56,) and DIIdiet+supplements (adjusted 















For mean daily intake of nutrient and food parameters of the index at 6-months (Table 2) 
there was a significantly higher intake of total fat, MUFA, omega-6, alcohol, vitamin E, 
flavones, flavonols and garlic and lower intake of trans fat in the MedDiet group compared to 
low-fat diet group.   
 
From baseline to 6-months there was a non-significant decrease in hs-CRP within the 
MedDiet group (-0.28 mg/L, p=0.38, 95% CI -0.91, 0.36) and the low-fat diet group (-0.16 
mg/L, p=0.73, 95% CI -1.13, 0.80). For hs-IL-6, there was also a non-significant decrease 
within the MedDiet group (-0.48 pg/mL, p=0.17, 95% CI -1.18, 0.21), but virtually no change 
within the low-fat diet group (-0.03 pg/mL, p=0.91, 95% CI -0.59, 0.53). The between-group 
changes as assessed by ANCOVA, with baseline marker levels and DII scores as covariates, 
demonstrated no significant difference between the MedDiet and low-fat diet group for hs-
CRP (adjusted difference 0.09 mg/L, p=0.84, 95%CI -0.80, 0.98) or hs-IL-6 (adjusted 
difference -0.32 pg/mL, p=0.29, 95%CI -0.93, 0.28). The results did not differ when the 
covariate of baseline DII scores was removed from the models.  
 
3.5. DII and MedDiet adherence  
 
In all participants, MEDAS score had a moderate, negative correlation with DII at baseline 
(r= -0.44, p=0.001) and a strong, negative correlation with DII at 6-months (r= -0.54, 
p<0.001), which was strengthened when we adjusted for diet study group (r= -0.70, 
p=0.001). The 6-month change variable for MEDAS score had a weak negative correlation 
with change in DII score (r= -0.29, p=0.03), however this correlation did not remain when 
study group was controlled for (r= -0.18, p=0.34). At 6-months, half (n=28) of the pooled 














had a significantly lower DII score compared to those with a MEDAS score <9 when 
adjusted for baseline DII score (-1.58 ± 2.70 vs. -0.04 ± 2.10, p=0.04, 95%CI 0.07, 2.40).  
 
Mean 6-month changes in DII scores, adjusted for baseline DII values, were 0.17 (95%CI -
0.708, 1.04), -1.17 (95%CI -2.24) and -1.29 (95%CI -2.47, -0.109) in tertiles 1 (-2 to 2 point 
change), 2 (3 to 5 point increase) and 3 (6 to 9 point increase) for change in MEDAS score, 
respectively. The mean adjusted changes across tertiles for DIIdiet+supplements were 0.17 
(95%CI -0.708, 1.04), -1.17 (95%CI -2.24, -0.094) and -1.29 (95%CI -2.47, -0.109), 
respectively. Table 3 presents the corresponding adjusted differences in mean values of 
change in DII score across tertiles of change in MEDAS, with T3 as the referent tertile. There 
were no significant differences across tertiles.  
 
Mean change in DII score (without supplements) between adherers and non-adherers to each 
of the MEDAS score components at 6-months are presented in Table 4. Participants who 
adhered to the recommendations for intake of olive oil as the main culinary fat and quantity, 
vegetables, legumes, nuts, white meat preferred to red/processed meat and sofrito sauce at 6-
months had a significantly greater reduction in DII score from baseline to 6-months than 





This study assessed both the theoretical and intervention effect on DII scores of a MedDiet 
versus low-fat diet in an Australian setting. Through analysis of our model meal plans, we 














had modest anti-inflammatory potential. In our pilot cohort of adult patients with CHD the 
MedDiet group adhered to the prescribed diet pattern and significantly reduced mean DII 
score after 6-months. By contrast, the low-fat diet did not influence DII score. After adjusting 
for baseline values, the MedDiet group significantly decreased mean DII score in comparison 
to the low-fat diet group. These results support our hypothesis that a MedDiet would improve 
DII score more significantly than a low-fat diet. Furthermore, when data for both intervention 
groups were pooled, greater MedDiet adherence scores significantly correlated with lower 
DII scores at baseline and 6-months. However, our results demonstrated that the MedDiet did 
not significantly reduce levels of inflammatory biomarkers hs-CRP and hs-IL-6, which was 
unexpected given the magnitude of improvement in DII score achieved with that diet.  
 
The high anti-inflammatory potential of a MedDiet model was previously demonstrated in a 
one-day meal plan based on traditional Cretan MedDiet principles[20]. The analysis in that 
study also included the full 45 parameters of the index and produced a highly anti-
inflammatory DII score of -3.96, which is comparable to the total score of -4.55 for our 2-
week MedDiet meal plan. The slightly lower DII score of our MedDiet could be explained by 
the incorporation of additional herbs and spices, its higher isoflavone content due to inclusion 
of soy and linseed bread, which also has a high content of omega-3 PUFA, and a 2-week 
period with increased capacity to capture greater food and nutrient variety.  
 
Despite both interventions representing healthy dietary patterns, the meal plan for the 
MedDiet had much greater anti-inflammatory potential than that of the low-fat diet. For the 
MedDiet model there were higher concentrations of nutrient components which are anti-
inflammatory in the index, including MUFA, PUFA, fiber, alcohol, vitamins and flavonoids. 














wine in the MedDiet. The low-fat meal plan had a higher content of carbohydrates, protein 
and cholesterol, which are each pro-inflammatory parameters of the index. Previously, higher 
participant adherence to healthy low-fat diet patterns has been demonstrated to be associated 
with lower DII scores[9]. However, our results are the first to show the theoretical DII score 
for a low-fat diet model.  
 
Adherence to the MedDiet in our multi-ethnic cohort was inversely related to DII at baseline 
and 6-months. Our experimental data also demonstrated increasing MedDiet adherence score 
correlated with a lowering of DII; however, this was not significant when diet study group 
was accounted for. The association between higher adherence to a traditional MedDiet 
pattern and a lower DII score has previously been demonstrated in cross-sectional analyses. 
In over 7,000 Spanish participants enrolled in the PREDIMED trial, adherence to the 
MedDiet was higher in the lowest quintile of DII scores[16]. In a cohort of over 40,000 
Australian, Italian or Greek-born Australians, there was an inverse correlation between the 
DII and MedDiet score[21].   
 
Despite clear evidence to support the anti-inflammatory DII of the traditional MedDiet 
pattern, it had not previously been shown how a MedDiet intervention can change dietary 
intake and subsequently DII scores. This was important to consider in our non-Mediterranean 
cohort, where adherence to a MedDiet was low at baseline and a low-fat diet is still 
considered the standard recommendation. Our results demonstrated that a MedDiet 
intervention can be adhered to and leads to a significant reduction in DII score in a multi-
ethnic cohort with chronic cardiovascular disease. Comparatively, prescription of the low-fat 
diet did not significantly change DII. We must recognize that in this cohort of patients with 














entering this study. Nonetheless, the theoretical and actual scope for improvement in DII with 
a low-fat diet was much lower than the MedDiet. At the end of the interventions, significant 
dietary intake differences between the groups mirrored many of the differences in the two 
model meal plans (such as dietary fats, alcohol, vitamin E and flavonoids).  
 
Our findings add to the limited available literature testing the effect of healthy diet 
interventions on the DII. Randomization to plant-based diets (total n=63) demonstrated a 
vegan, vegetarian and pesco-vegetarian diet each reduced mean DII significantly (by -1.5, -
1.4 and -1.6, respectively) after 2 months in a predominately female cohort[22]. However, 
these improvements in DII scores were not maintained at 6-months. Furthermore, there was 
limited improvement in that trial’s control groups prescribed healthy semi-vegetarian and 
omnivorous[22] diets, which had similar dietary prescription to our low-fat diet group. In a 
large cohort of postmenopausal women low-fat diet intervention achieved a modest reduction 
in DII score (by -0.16) between 1-year and 6-years follow-up[23]. Both of these previous 
trials assessed only a subset of the 45 DII parameters, 27 and 32 respectively, therefore their 
findings may not truly reflect the diets’ inflammatory potential.  
 
We hypothesized that improvement in DII with our MedDiet intervention would affect 
inflammatory markers. However, our results showed that in this pilot cohort of patients with 
CHD the MedDiet did not significantly improve hs-CRP or hs-IL-6. When adjusting for 
baseline DII score, a promising trend was observed regarding a greater reduction in hs-IL-6 
in the MedDiet, compared to low-fat diet participants. A significant effect of the MedDiet 
compared to control diets in intervention trials on both CRP (14 studies) and IL-6 (6 studies) 
has previously been confirmed[6]. However, a recent systematic review[7] which explored 














found that there was no significant effect of Mediterranean-type diets compared to low-fat 
diets on CRP (4 studies)[51-54], and three of those studies also had small sample sizes 
(n<100). Current treatment regimens for patients with diagnosed CHD include intensive 
pharmacotherapy[55]. In particular, both aspirin and statin medication have pleiotropic anti-
inflammatory effects, which have been proposed to provide additional explanation for the 
impact which these medications have on reducing secondary CHD events[56, 57]. For hs-
CRP, mean baseline levels in this AUSMED cohort were well within the normal range 
(<3mg/L)[49]; hence, they may have had limited scope for improvement in this marker.  
 
Observational studies have demonstrated that a more pro-inflammatory DII is associated with 
higher circulating levels of inflammatory markers CRP[12] and IL-6[14].However, the effect 
of prospective changes in DII scores on these markers has not previously been tested and the 
existing studies were not conducted in populations on intensive medications, such as our 
CHD cohort.  The association between DII and inflammatory markers has not been validated 
in patients with CHD. In the current AUSMED cohort, we have demonstrated (Mayr, et al., 
2017, Companion Paper 2) that higher DII score had a nonsignificant association with an 
increased odds of elevated hs-CRP (>3 mg/L) at baseline (OR=1.16, 95%CI 0.89, 1.51).  
 
Assessment of all 45 intake parameters of the DII strengthens our results. The MedDiet 
differs from other healthy dietary patterns through culinary aspects such as use of herbs and 
spices and other plant-foods high in flavonoids. When these parameters are not included in 
the DII calculation, the anti-inflammatory potential of the MedDiet, particularly in 
comparison to the low-fat diet which does not necessarily include these components, could be 
underestimated. Our participants’ nutrient and food intake data were collected via 7-day food 














result in more accurate DII scores than with use of food frequency questionnaires or 24-h 
dietary records, which are the most common methods used in other published analyses[11]. 
Our DII calculation also adjusted for supplement use.  
 
Alongside our study’s strengths and its novel findings, we must acknowledge some 
limitations. We had a small sample size, nine drop-outs were not included in our analysis and 
these participants had higher (more pro-inflammatory) DII scores at baseline. The majority of 
included participants were male, mean DII for both study groups was anti-inflammatory at 
baseline and mean hs-CRP levels were within the normal range. Our cohort is representative 
of patients with CHD on intensive pharmacotherapy, and who are potentially motivated and 
health conscious. Therefore, our results were affected by inadequate statistical power and are 
not necessarily applicable to healthy subjects, other disease populations or women. 
Participants in the MedDiet group in this study were given food hampers to facilitate 
compliance, which is not reflective of a real-world setting. Our assessment for flavonoid 
intake was estimated using databases from the United States which may not accurately reflect 
Australian food composition. Our assessment of omega-6 was limited to linoleic acid. 
Finally,  our analyses were not based on intention-to-treat as the study was designed to test 
changes in DII score in participants who completed a dietary intervention. Future research 
should test whether the reduction in DII achieved by the MedDiet leads to an improvement in 
markers of inflammation (including markers in addition to CRP and IL-6) in a larger sample, 
or other cohorts including healthy subjects and individuals with other comorbidities. 
 
We have demonstrated that a model MedDiet based on traditional principles of the diet is 
theoretically more anti-inflammatory than a low-fat diet. Furthermore, 6-month intervention 














and lead to a significant improvement in DII scores. A low-fat diet did not improve DII 
scores in this patient group. The reduction in DII scores from consumption of this MedDiet 
tended to improve the inflammatory marker hs-IL-6 and this could be related to a reduction in 
risk of CHD. However, future studies in larger, well-powered samples and other population 
groups are needed to confirm whether reduction in DII scores through MedDiet intervention 
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Figure Captions   
 
Figure 1. Study flow diagram of AUSMED participant appointments from 
randomization to diet study groups to end of intervention, 2014-2016. MedDiet, 
Mediterranean diet; AMI, acute myocardial infarction.  
 
Figure 2. DII scores at baseline and 6-months in the Low-fat diet and Mediterranean 
diet study groups. Values are presented as means ± SEM. DII, dietary inflammatory index; 
MedDiet, Mediterranean diet. *Significant difference between study groups at that time point, 
Independent Student’s T-test, p<0.025 (Bonferroni correction applied). †Significant 
difference to baseline within diet intervention group, Paired samples T-test, p<0.05. 
‡Significant difference between diet intervention groups for change in DII score, ANCOVA 
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Acute myocardial infarction 
Coronary artery bypass grafting 
Percutaneous coronary intervention 
Time since event (months)
c
















Type 2 diabetes mellitus   9 (31.0) 7 (25.9) 0.90 





Angiotensin 2 receptor blocker  
Calcium-channel blocker 



































Vitamin E  

































Current smoker  
Cardiac rehabilitation  





















   
-0.17± 2.27 
-0.33 ± 2.29 
-0.40 ± 3.14 
-0.64 ± 3.19 
0.75 
0.68  














Abbreviations: MedDiet, Mediterranean diet; ACE, angiotensin converting enzyme; MVPA, 
moderate-to-vigorous physical activity; DII, Dietary Inflammatory Index.  
a
Values are n (%), means ± SD or medians (IQR). 
b
Chi square test of independence, Independent Student’s T-test or Mann-Whitney U test.  
c
Non-parametric continuous variables, presented as Medians (IQR).  


























Table 2. Parameters and scores of DII for the AUSMED Low-fat diet and 
Mediterranean diet intervention meal plans and participant intake at 6-months
a
  
DII Meal Plans Intake at 6-months 
Intake Parameter Low-fat diet MedDiet Low-fat diet MedDiet P
b
 
Energy (kcal) 2068.23 2240.90 1823.30 ± 551.1 2030.04 ± 486.5 0.08 
Protein (g) 99.73 87.32 96.14 ± 25.8 92.08 ± 26.6 0.28 
Carbohydrate (g) 277.10 194.00 194.60 ± 67.5 176.61 ± 54.3 0.30 
Fat (g) 53.19 105.96 63.93 ± 29.1 91.64 ± 30.8 <0.001* 
MUFA (g) 21.28 52.45 24.85 ± 12.4 46.51 ± 18.5 <0.001* 
PUFA (g) 10.58 24.76 12.07 ± 7.2 17.25 ± 7.8 0.004* 
Omega-3 (g) 1.26 5.87 1.98 ±0.8 2.59 ± 1.6 0.07 
Omega-6 (g) 9.14 18.66 9.85 ± 6.7 14.41 ± 6.6 0.01* 
Saturated fat (g) 16.06 20.85 21.02 ± 10.5 20.70 ± 6.4 0.56 
Trans fat (g) 0.65 0.58 0.95 ± 0.6 0.65 ± 0.3 0.02* 
Cholesterol (mg) 340.95 255.75 307.44 ± 152.6 268.51 ± 128.4 0.22 
Fiber (g) 32.88 41.08 28.17 ± 8.9 31.57 ± 11.1 0.21 
Alcohol (g) 0.00 11.12 3.32 ± 6.8 8.98 ± 11.3 0.01* 
Caffeine (g) 0.08 0.14 0.21 ± 0.3 0.14 ± 0.1 0.56 
Folate (μg) 580.38 732.31 536.14 ± 192.6 521.91 ± 167.5 0.94 
Beta carotene (μg) 2844.89 3039.02 3297.3 ± 1818.9 4130.52 ± 2521.8 0.25 
Vitamin A (RE)   844.20 2161.56 889.38 ± 407.4 1015.70 ± 567.0 0.59 
Vitamin B6 (mg) 1.30 2.21 1.85 ± 2.1 1.68 ± 0.7 0.54 
Vitamin B12 (μg)  4.40 7.02 5.36 ± 5.1 4.09 ± 2.1 0.10 
Vitamin C (mg) 126.21 191.82 127.86 ± 102.8 123.34 ± 80.9 0.75 
Vitamin D (μg) 1.45 3.17 2.22 ± 2.8 3.85 ± 4.6 0.14 
Vitamin E (mg) 10.57 29.27 11.35 ± 5.9 20.10 ± 6.4 <0.001* 
Iron (mg) 13.10 15.27 11.41 ± 3.5 12.20 ± 3.3 0.39 
Magnesium (mg) 399.83 462.78 345.61 ± 108.9 375.60 ± 95.9 0.28 
Niacin (mg) 23.12 20.22 24.57 ± 8.2 22.39 ± 7.0 0.34 
Riboflavin (mg)  1.90 1.85 1.85 ± 0.8 1.72 ± 0.5 0.48 
Selenium (μg)  116.81 82.84 89.20 ± 25.0 99.32 ± 36.1 0.34 
Thiamin (mg) 1.52 1.31 1.58 ± 0.7 1.33 ± 0.5 0.28 
Zinc (mg) 11.36 11.68 10.96 ± 3.0 9.92 ± 2.6 0.14 
Flavan-3-ol (mg) 12.02 44.73 288.44  ± 369.8 361.96 ± 359.5 0.47 
Flavones (mg) 2.72 14.02 2.97 ± 6.4 3.30 ± 5.3 0.003* 
Flavonols (mg) 20.64 36.63 21.78 ± 15.7 33.65 ± 23.6 0.03* 
Flavonones (mg) 12.97 13.21 10.51 ± 13.7 13.37 ± 20.6 0.33 
Anthocyanidins (mg) 7.01 72.84 23.38 ± 23.8 20.73 ± 13.6 0.75 
Isoflavones (mg) 0.26 15.46 0.52 ± 0.9 1.47 ± 2.4 0.59 
Eugenol (mg) 0.00 1.53 0.00 ± 0.0 0.22 ± 1.1 0.30 
Green/black tea (g) 0.00 0.36 2.65 ± 3.2 3.20 ± 3.1 0.48 
Garlic (g) 0.73 1.73 0.21 ± 0.5 0.70 ± 1.0 0.03* 
Ginger (g) 0.29 0.00 0.11 ± 0.3  0.12 ± 0.6 0.27 
Onion (g) 24.57 58.55 15.92 ± 22.2 24.28 ± 32.9 0.14 
Pepper (g) 0.27 0.36 0.02 ± 0.0 0.05 ± 0.1 0.77 
Rosemary (mg) 0.09 71.43 0.81 ± 3.2  16.82 ± 67.6 0.32 
Saffron (g) 0.00 0.00 0.00 ± 0.0 0.002 ± 0.0 0.30 
Turmeric (mg) 0.00 0.00 9.75 ± 38.6 28.04 ± 145.7 0.63 
Thyme/oregano (mg) 0.00 540.00 2.17 ± 9.1 22.95 ± 72.3 0.17 
DII
c














The 45 intake parameters listed represent all which are included in the DII. The meal plans 
modeled the diet interventions for the low-fat diet (1-week) and the MedDiet (2-weeks). 
Dietary intake of the parameters by the low-fat diet (n=29) and MedDiet (n=27) participants 
at 6-months represents intake from foods only with supplement intake excluded.  
Abbreviations: DII, dietary inflammatory index; MedDiet, Mediterranean diet; MUFA, 
mono-unsaturated fatty acids; PUFA, polyunsaturated fatty acids; RE, retinol equivalents. 
 
a
Values are daily intake for the meal plans and means ± SD for intake at 6-months. 
 
b
Differences between intake of the study groups at 6-months, Independent Student’s T-test or 
Mann-Whitney U test.  
c
Negative number reflects an anti-inflammatory score, while positive number reflects a pro-
inflammatory score.  
*Significant difference in intake of that parameter between the MedDiet and low-fat diet 



















Table 3. Adjusted mean differences in the 6-month change in DII scores between 





-2 to 2 
T2 
3 to 5 
T3 




Participants (n)  25 17 14  
Change in DII  1.38 -0.08, 2.83 0.06 -1.54, 1.66 0 Reference 0.08 
Change in 
DIIdiet+supplements 
1.46 -0.01, 2.93 0.12 -1.49, 1.73 0 Reference 0.07 
Participants were distributed into tertiles of 6-month change in MEDAS score based on 
having an equal number of participants across three groups using SPSS statistical software.  
Abbreviations: MEDAS, Mediterranean Diet Adherence Screener; DII, dietary inflammatory 
index; T, tertile.   
a














































Olive oil main fat  17 0.65 ± 2.1 39 -1.05 ± 2.7 1.45 0.21, 2.70 0.02* 
Olive oil quantity /d 49 -0.27 ± 2.5 7 -2.38 ± 3.3 2.31 0.60, 4.01 0.009* 
Vegetable serves /d 21 0.23 ± 2.2 35 -0.99 ± 2.8 1.57 0.40, 274 0.01* 
Fruit serves /d 36 -0.70 ± 2.6 20 -0.23 ± 2.7 0.81 -0.53, 2.15 0.23 
Red/processed meat serves /d 14 0.14 ± 2.4 42 -0.76 ± 2.7 1.24 -0.11, 2.60 0.07 
Butter/ marg. /cream serves /d 6 -0.36 ± 2.4 50 -0.55 ± 2.7 0.46 -1.48, 2.40 0.64 
Sugar-sweetened drinks /d  4 -0.99 ± 3.0 52 -0.50 ± 2.6 1.28 -1.14, 3.69 0.29 
Wine glasses /wk  46 -0.48 ± 2.8 10 -0.76 ± 1.9 1.04 -0.54, 2.61 0.19 
Legumes serves /wk  29 0.02 ± 2.1 27 -1.09 ± 3.0 1.48 0.34, 2.62 0.01* 
Fish or seafood serves /wk 16 -0.78 ± 2.1 40 -0.44 ± 2.8  0.33 -1.03, 1.68 0.63 
Commercial sweets /wk  14 -0.69 ± 2.7 42 -0.48 ± 2.7 0.41 -1.00, 1.81 0.56 
Nuts serves /wk  16 -0.31 ± 2.3 40 -0.62 ± 2.8 1.46 0.11, 2.80 0.03* 
Poultry preferred to red meats 13 0.82 ± 2.5 43 -0.94 ± 2.6 1.83 0.50, 3.16 0.008* 
Use of sofrito sauce /wk  36 -0.26 ± 2.4 20 -1.03 ± 3.0 1.46 0.25, 2.68 0.02* 
The MEDAS scoring tool was used to assess Mediterranean diet adherence in all study 
participants. Each of its 14 components represent a food group based intake recommendation. 
The data represents changes in DII score according to whether participants adhered to each of 
those recommendations or not at 6-months.    
Abbreviations: DII; dietary inflammatory index; MEDAS, Mediterranean diet adherence 
screener; marg, margarine.  
a
Values are participants (n) and means ± SD.  
b
Adjusted mean differences (95%CIs, p-values) between adherers and non-adherers, 
ANCOVA adjusted for baseline DII scores.  
*Significant difference for mean 6-month change in DII score between adherers and non-
adherers to that MEDAS component at 6-months, p<0.05.  
ACCEPTED MANUSCRIPT
Figure 1
Figure 2
